Objective: To evaluateclinical features, treatment and outcomes of patients diagnosed with primary breast diffuse large B-cell lymphoma（DLBCL）.
Methods: Clinical data were analyzed for all patients diagnosed with primary breast DLBCL（n=21）. Kaplan-Meier method was used to estimate 5- year overall survival（OS）rate, and the difference was compared by Log- rank test.
Results: The 21 cases of patients with primary breast DLBCL were all female with median age at diagnosis as 48 years （range 21-64 years）. 13 patients had International Prognostic Index（IPI）of 0, 6 IPI 1, and 2 IPI 2. The 5- year OS rates of CHOP/R- CHOP and R±DICE after R±EPOCH groups were 40.0% and 72.2% , respectively（P=0.035）. The central nervous system relapse rate of CHOP/R-CHOP and R±DICE after R± EPOCH groups were 16.7% and 6.7%（P=0.500）, respectively. The 5- year OS rates of patients with primary breast DLBCL staging Ⅱ E-Ⅲ E and Ⅰ E were 21.4% and 83.3% , respectively（P=0.025）.
Conclusion: Primary breast DLBCL was rare. The patients of primary breast DLBCL with chemotherapy regimen of R±DICE after R±EPOCH might have a better prognosis and lower relapse rate of central nervous system; the primary breast DLBCL patients staging ⅡE-ⅢE might have a poor prognosis.
目的: 探讨原发乳腺弥漫大B细胞淋巴瘤(DLBCL)患者的临床特征、治疗及预后。
方法: 回顾性分析21例原发乳腺DLBCL患者的临床资料，用Kaplan-Meier法分析5年总生存(OS)率，采用Log-rank检验法进行亚组间差异性分析。
结果: 21例患者均为女性，中位年龄48(21~64)岁，其中国际预后指数(IPI)评分0分者13例，1分者6例，2分者2例。21例患者中R-CHOP/CHOP方案治疗组(6例)和EPOCH±R序贯DICE±R方案治疗组(15例)患者的5年OS率分别为40.0％和72.2%，差异有统计学意义(P=0.035)；中枢神经系统复发率分别为16.7％和6.7%(P=0.500)；ⅡE~ⅢE期组(9例)和ⅠE期(12例)患者5年OS率分别为21.4％和83.3%，差异有统计学意义(P=0.025)。
结论: 原发乳腺DLBCL临床少见，EPOCH±R序贯DICE±R方案治疗可改善患者预后，降低中枢神经系统复发率；ⅡE~ⅢE期者较ⅠE期者预后更差。